Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 2883.1.

https://doi.org/10.1182/blood-2024-201478

Published: 2024

Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

Frances M. Cole, George S. Laszlo, Margaret C. Lunn-Halbert, Allie R. Kehret, Patrick A. Zweidler-McKay, Eduardo Rodríguez-Arbolí, David Wu, Kyle E. Nyberg, Junyang Li, Sheryl Y. T. Lim, Sribalaji Lakshmikanthan, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2024-200907

Published: 2024

Journal Articles

Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Antonio Solana-Altabella, Irene Navarro Vicente, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares, Tamara Castaño, Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepción, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla-Rubira, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal, Laura Lamarca Eraso, Mar Tormo, Carmen Botella, Mercedes Colorado, Manuel Barrios García, Rebeca Rodriguez-Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 320.

https://doi.org/10.1182/blood-2024-205106

Published: 2024

Journal Articles

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Irene Navarro Vicente, Antonio Solana-Altabella, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares Gil, Tamara Castaño, Jesús Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepcion, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal Toscano, Laura Lamarca, Mar Tormo, Cristina Gil, Mercedes Colorado, Manuel Barrios García, Matxalen Olivares Salaverri, Lisette Costilla-Barriga, Rebeca Rodriguez Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 319.

https://doi.org/10.1182/blood-2024-205172

Published: 2024

Journal Articles

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Eduardo Rodriguez Arboli, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Jose Ángel Raposo Puglia, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordoñez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, David Martinez-Cuadron, Jorge Labrador

Blood (2024) 144 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2024-204779

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Phuong T Vo, Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Chris Davis, Ryan S. Basom, Rainer F. Storb, Roland B. Walter

Blood (2024) 144 (Supplement 1): 7314.

https://doi.org/10.1182/blood-2024-206221

Published: 2024

Journal Articles

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 737.

https://doi.org/10.1182/blood-2024-207953

Published: 2024

Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Margaret C. Lunn, George S. Laszlo, Sarah Eraiss, Mark T. Orr, Heidi K. Jessup, Henry Chan, Heather J. Thomas, Ann F. Cheung, Gregory P. Chang, Asya Grinberg, Eduardo Rodríguez-Arbolí, Sheryl Y. T. Lim, Allie R. Kehret, Jenny Huo, Frances M. Cole, Samuel C. Scharffenberger, Roland B. Walter

Blood (2023) 142 (Supplement 1): 1431.

https://doi.org/10.1182/blood-2023-185432

Published: 2023

Journal Articles

Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Naveed Ali, Othus Megan, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2023-183117

Published: 2023

Journal Articles

Graft Versus Host Disease Prophylaxis with Tacrolimus, Sirolimus and MMF in Patients Undergoing Reduced Intensity Conditioning Allogeneic Transplantation

Blood (2023) 142 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2023-185757

Published: 2023

Journal Articles

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2023-188633

Published: 2023

Journal Articles

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Daniel J Olivieri, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Irum Khan, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2023-181244

Published: 2023

Journal Articles

Stem Cells and Leukemic Stem Cells As a Prognostic Factor in Acute Myeloid Leukemia

Olga Pérez-López, Marta Reinoso Segura, Clara B. Calderon Garcia, Noelia González-Carrasco, María Solé, Eduardo Rodriguez Arboli, Concepción Prats-Martín, Jose González Campos, Jose A. Perez-Simon, Teresa Caballero

Blood (2022) 140 (Supplement 1): 3446–3447.

https://doi.org/10.1182/blood-2022-169528

Published: 2022

Journal Articles

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Jose F. Falantes, Francisco J. Márquez-Malaver, Estrella Carrillo-Cruz, Rosario M Morales-Camacho, Concepción Prats-Martín, Teresa Caballero, Eduardo Rodriguez Arbolí, Ildefonso Espigado, Jose A. Perez-Simon

Blood (2022) 140 (Supplement 1): 6920–6922.

https://doi.org/10.1182/blood-2022-169372

Published: 2022

Journal Articles

Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials

Eduardo Rodriguez Arbolí, Catherine J. Lee, Teresa Caballero, Clara Garcia-Calderon, Carmen Martinez, Maria Aranzazu Bermudez, Lucía López Corral, Ana Triguero, Lynn E. Onstad, Stefanie Sarantopoulos, Stephanie J. Lee, Jose A. Perez-Simon

Blood (2022) 140 (Supplement 1): 10502–10504.

https://doi.org/10.1182/blood-2022-158230

Published: 2022

Journal Articles

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Blood (2021) 138 (Supplement 1): 872.

https://doi.org/10.1182/blood-2021-147735

Published: 2021

Journal Articles

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Teresa Caballero, Olga Pérez-López, Ana Yeguas Bermejo, Eduardo Rodriguez Arbolí, Enrique Colado Varela, Maria Desamparados Sampere Talens, María Belén Vidriales, Covadonga Quirós Caso, Marta Reinoso Segura, Concepción Prats-Martín, Pau Montesinos, Jose A. Perez-Simon

Blood (2021) 138 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2021-151533

Published: 2021

Journal Articles

Similar Probabilities of Failure to Reach Transplantation and Transplant Outcomes after HLA-Identical Sibling or Unrelated Donor Transplant in Patients with Acute Myeloid Leukemia: A Single Institution Evaluation of a Donor Selection Algorithm

Eduardo Rodríguez-Arbolí, MD, Francisco J. Márquez-Malaver, RN, Nancy Rodríguez-Torres, MD, Teresa Caballero-Velázquez, MD PhD, Virginia Escamilla Gomez, Cristina Calderón-Cabrera, MD, José F. Falantes, MD, Ildefonso Espigado, MD PhD, José A. Pérez-Simón

Blood (2017) 130 (Supplement 1): 5548.

https://doi.org/10.1182/blood.V130.Suppl_1.5548.5548

Published: 2017

Journal Articles

CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience

Blood (2017) 130 (Supplement 1): 3208.

https://doi.org/10.1182/blood.V130.Suppl_1.3208.3208

Published: 2017

NARROW

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16/NKG2D Immune Modulating TriNKET ® BMS-986357 (CC-96191)

Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Graft Versus Host Disease Prophylaxis with Tacrolimus, Sirolimus and MMF in Patients Undergoing Reduced Intensity Conditioning Allogeneic Transplantation

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Stem Cells and Leukemic Stem Cells As a Prognostic Factor in Acute Myeloid Leukemia

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Prognosis Value of Measurable Residual Disease By Multiparameter Flow Cytotometry in Patients with Acute Myeloblastic Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation

Similar Probabilities of Failure to Reach Transplantation and Transplant Outcomes after HLA-Identical Sibling or Unrelated Donor Transplant in Patients with Acute Myeloid Leukemia: A Single Institution Evaluation of a Donor Selection Algorithm

CCR6, IL7R, FAS and Madcam-1 Single Nucleotide Polymorphisms Are Associated with Higher Incidence of Infections in Allogeneic Stem-Cell Transplant from a Related Donor after a Reduced Intensity Conditioning Regimen: A Multicenter Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only